ChromaDex® CEO to Chair Conference Session on Quality Control for Dietary Supplements

Apr 15, 2013, 05:30 ET from ChromaDex

IRVINE, Calif., April 15, 2013 /PRNewswire/ -- ChromaDex Corporation® (OTCQB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, announced today members of its management team will be active participants at the 12th Annual Oxford International Conference on Science and Botanicals, which begins on April 15, 2013.


ChromaDex's co-founder and CEO, Frank Jaksch, will be a panelist and chair for the session titled, "Quality Control for Dietary Supplements."  Another panelist for that session includes Cara Welch, Ph.D., Senior Vice President of Scientific and Regulatory Affairs at the Natural Products Association.

Also at the conference will be Nancy Booth, Ph.D., Senior Science Director at Spherix Consulting, a division of ChromaDex.  Dr. Booth will be a panelist on the session titled, "Botanicals Impact on Human Health," and will deliver a presentation on the "Principles of Safety Assessment of Natural Products for use in Foods and Supplements."

The conference is supported in part by a cooperative agreement between the University of Mississippi's National Center for Natural Products Research (NCNPR) and the Center for Food Safety and Applied Nutrition (CFSAN) at the US Food and Drug Administration (FDA). The conference draws scientists from around the world to discuss medicinal plants and dietary supplements as well as the latest research innovations in such areas as natural products chemistry, pharmacognosy and botanicals.

About ChromaDex®:
ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model which utilizes its wholly-owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The Company provides seamless science-based solutions to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. Our ingredient technologies unit includes products backed with extensive scientific research and intellectual property. The ingredient portfolio includes pTeroPure® pterostilbene; ProC3G™, a natural black rice containing cyanidine-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; nutraGac™, a gac fruit powder; curcumin and nicotinamide riboside, a novel next-generation B-vitamin currently under development. To learn more about ChromaDex please visit

Forward-Looking Statements:
Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

ChromaDex Investor Contact:         
The Del Mar Consulting Group, Inc.
Robert B. Prag, President


Alex Partners, LLC
Scott Wilfong, President

ChromaDex Contact:
Laura Carney, Executive Assistant

The statements in this press release have not been evaluated by the Food and Drug Administration.  Products are not intended to diagnose, treat, cure or prevent any disease.

SOURCE ChromaDex